Related references
Note: Only part of the references are listed.Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
Arnon P. Kater et al.
HAEMATOLOGICA (2019)
Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome
Hawk Kim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion
Daniela Asslaber et al.
BLOOD (2019)
Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS
Stefania Fiorcari et al.
LEUKEMIA (2019)
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL)
Christine I. Chen et al.
LEUKEMIA & LYMPHOMA (2019)
In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment
Csilla Kriston et al.
ANNALS OF HEMATOLOGY (2018)
EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes
Kinga Szurian et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2018)
IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q-AML
Belen Lopez-Millan et al.
ONCOIMMUNOLOGY (2018)
Lenalidomide in the treatment of chronic lymphocytic leukemia
Gilad Itchaki et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
Anna Maria Fink et al.
LANCET HAEMATOLOGY (2017)
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity
Patrick R. Hagner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Candida Vitale et al.
CLINICAL CANCER RESEARCH (2016)
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
Athena Kritharis et al.
BLOOD (2015)
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia
Stefania Fiorcari et al.
HAEMATOLOGICA (2015)
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
Jessie-F. Fecteau et al.
BLOOD (2014)
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia
Rossana Maffei et al.
EXPERIMENTAL HEMATOLOGY (2014)
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
C. C. Bjorklund et al.
LEUKEMIA (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
Jan A. Burger et al.
SEMINARS IN CANCER BIOLOGY (2014)
Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
Andrea Acebes-Huerta et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma
Mark Plander et al.
ANNALS OF HEMATOLOGY (2011)
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
Asher A. Chanan-Khan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
Carlo Calissano et al.
MOLECULAR MEDICINE (2011)
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella et al.
BLOOD (2010)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2008)
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
Valter Gattei et al.
BLOOD (2008)
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Share Paper
